# Cizzle Biotechnology 2025 results highlight licensing and clinical progress

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-2025-results-highlight-licensing-and-clinical-progress/4121250231
- Published: 2026-04-30T07:30:35+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc** (LON:CIZ), the UK based diagnostics developer
of early cancer tests, has announced the publication of the Company’s Annual Report
and Financial Statements for the year ended 31 December 2025.

The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/
4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National
Storage Mechanism (NSM) and the Company’s website: https://cizzlebiotechnology.com

**Executive Chair’s Statement**

I am pleased to present the Annual Report for the year ended 31 December 2025 which
has been a period of strategic advancement and commercial momentum for the Group.
The year marked a transitional period as we moved from a development-focused organisation
towards commercial execution. Our core mission continues to be the transformation
of lung cancer outcomes by enabling earlier detection through a costeffective and
scalable blood test that measures the CIZ1B biomarker, which has shown high sensitivity
for early-stage disease.

[4787C_1-2026-4-29](https://www.directorstalkinterviews.com/wp-content/uploads/2026/04/4787C_1-2026-4-29.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/04/4787C_1-2026-4-29.pdf)

Share on:
